Suchergebnisse - (Subject:"Adalimumab")

PubPharm (12.467)

151

Implementation of risk minimization measures to reduce the risk of tuberculosis among tumor necrosis factor medication users

enthalten in: Pharmacoepidemiology and drug safety | 2024

von Al-Fadel, N. | Almutairi, A. | Aldhirgham, T. | +3

152

Tumor necrosis factor-α inhibitor treatment of acne fulminans - a clinical and literature review

enthalten in: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG | 2024

von Taudorf, E. | Jensen, M. | Bouazzi, D. | +4

153

Cerebral Tuberculosis After Therapy With Adalimumab for Hidradenitis Suppurativa : A Rare Case

enthalten in: Cureus | 2024

von Martins, F. | Rodrigues, A. | Fonseca Oliveira, J. | +2

154

Development of Morphea Following Treatment with an ADA Biosimilar : A Case Report

enthalten in: Current rheumatology reviews | 2024

von Venetsanopoulou, A. | Mavridou, K. | Pelechas, E. | +2

155

Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α

enthalten in: Frontiers in immunology | 2024

von Spencer, E. | Dubinsky, M. | Kamm, M. | +9

156

HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis

enthalten in: Annals of the rheumatic diseases | 2024

von Yap, C. | Nair, N. | de Vries, A. | +7

157

The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira

enthalten in: Therapeutic advances in chronic disease | 2024

von McClellan, J. | Ómarsdóttir, S. | Roy, N. | +3

158

Identification of patient endotypes and adalimumab treatment responders in axial spondyloarthritis using blood-derived extracellular matrix biomarkers

enthalten in: RMD open | 2024

von Port, H. | Christiansen, F. | Nielsen, S. | +9

159

Albumin change predicts failure in ulcerative colitis treated with adalimumab

enthalten in: PloS one | 2024

von Ishida, N. | Takahashi, K. | Asai, Y. | +8

160

Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis

enthalten in: Ocular immunology and inflammation | 2024

von Song, S. | Woo, S.